These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 9305636

  • 1. Bivalence of EGF-like ligands drives the ErbB signaling network.
    Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y.
    EMBO J; 1997 Aug 15; 16(16):4938-50. PubMed ID: 9305636
    [Abstract] [Full Text] [Related]

  • 2. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 3. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
    Graus-Porta D, Beerli RR, Daly JM, Hynes NE.
    EMBO J; 1997 Apr 01; 16(7):1647-55. PubMed ID: 9130710
    [Abstract] [Full Text] [Related]

  • 4. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
    Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y.
    EMBO J; 1996 Jan 15; 15(2):254-64. PubMed ID: 8617201
    [Abstract] [Full Text] [Related]

  • 5. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 6. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
    Pinkas-Kramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, Yarden Y.
    EMBO J; 1996 May 15; 15(10):2452-67. PubMed ID: 8665853
    [Abstract] [Full Text] [Related]

  • 7. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
    Chang H, Riese DJ, Gilbert W, Stern DF, McMahan UJ.
    Nature; 1997 May 29; 387(6632):509-12. PubMed ID: 9168114
    [Abstract] [Full Text] [Related]

  • 8. Neu and its ligands: from an oncogene to neural factors.
    Peles E, Yarden Y.
    Bioessays; 1993 Dec 29; 15(12):815-24. PubMed ID: 7908191
    [Abstract] [Full Text] [Related]

  • 9. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor.
    Azios NG, Romero FJ, Denton MC, Doherty JK, Clinton GM.
    Oncogene; 2001 Aug 23; 20(37):5199-209. PubMed ID: 11526509
    [Abstract] [Full Text] [Related]

  • 10. Regulation of cyclooxygenase-2 pathway by HER2 receptor.
    Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R.
    Oncogene; 1999 Jan 14; 18(2):305-14. PubMed ID: 9927187
    [Abstract] [Full Text] [Related]

  • 11. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases.
    Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C.
    Nature; 1997 May 29; 387(6632):512-6. PubMed ID: 9168115
    [Abstract] [Full Text] [Related]

  • 12. Epidermal growth factor mutant with wild-type affinity for both ErbB1 and ErbB3.
    Wingens M, Jacobs-Oomen S, van der Woning SP, Stortelers C, van Zoelen EJ.
    Biochemistry; 2006 Apr 11; 45(14):4703-10. PubMed ID: 16584205
    [Abstract] [Full Text] [Related]

  • 13. Signal transduction and oncogenesis by ErbB/HER receptors.
    Marmor MD, Skaria KB, Yarden Y.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):903-13. PubMed ID: 14967450
    [Abstract] [Full Text] [Related]

  • 14. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
    Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M.
    Oncogene; 1997 May 01; 14(17):2099-109. PubMed ID: 9160890
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 17. Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
    Sanderson MP, Dempsey PJ, Dunbar AJ.
    Growth Factors; 2006 Jun 15; 24(2):121-36. PubMed ID: 16801132
    [Abstract] [Full Text] [Related]

  • 18. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 19. Type I growth factor receptors: current status and future work.
    Gullick WJ.
    Biochem Soc Symp; 1998 Jun 01; 63():193-8. PubMed ID: 9513723
    [Abstract] [Full Text] [Related]

  • 20. Affinity regulates spatial range of EGF receptor autocrine ligand binding.
    DeWitt A, Iida T, Lam HY, Hill V, Wiley HS, Lauffenburger DA.
    Dev Biol; 2002 Oct 15; 250(2):305-16. PubMed ID: 12376105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.